Molecular Test Detects Three Arboviruses in Plasma Samples
|
By LabMedica International staff writers Posted on 04 Aug 2016 |

Image: A digitally colorized transmission electron micrograph (TEM) of Zika virus. Viral particles are 40 nm in diameter with an outer envelope and dense inner core (Photo courtesy of Cynthia Goldsmith / CDC).
Currently, multiple arboviruses are circulating in Brazil: Zika, chikungunya and dengue and they have similar clinical pictures, which can lead to misdiagnosis based on clinical grounds alone.
Detection tests for viral ribonucleic acid (RNA) such as the quantitative reverse transcription polymerase chain reaction (RT-qPCR) can reliably and specifically distinguish the three viruses and the specific diagnosis can be important in anticipating, preventing, and managing complications.
Scientists at the Laboratório Sabin (Brasília, Brazil) and their colleagues collected 90 plasma samples from the routine arbovirus laboratory, 20 positive for Zika (RT-qPCR), six positive for chikungunya (RT-qPCR), 18 positive for dengue nonstructural protein 1 antigen test (NS-1) and 46 negative for all three viruses. Nucleic acids were extracted from 1mL of sample by using an automated DNA extractor. An in-vitro transcribed random RNA sequence, which is not found in the nature, was spiked into plasmas during the nucleic acids extraction to function as a process control. Primers/probes for chikungunya were specifically designed for this study.
Zika, chikungunya and dengue viruses were assessed simultaneously by RT-qPCR, but in independent reaction wells. The control RNA was co-amplified in all instances. The viral loads of specific samples were quantified against a serial dilution of synthetic single-stranded DNA (ssDNA) and the limits of detection of each assay were determined by probit regression analysis. To investigate the precision of the assays, three samples at ~72, ~7.2 and ~0.72 copies/mL of each viruses were evaluated by using the Clinical and Laboratory Standards Institute (CLSI) EP12-A2 method during five days in quadruplicate by two operators.
The investigators reported that the limits of detection were 26 copies/mL for Zika, 23.5 copies/mL, for chikungunya and 25.6 copies/mL for dengue. The ~72, ~7.2 and ~0.72 copies/mL samples yielded 18/20 (90%), 2/20 (10%) and 1/20 (5%) positive results for Zika, 18/20 (90%), 4/20 (20%) and 0/20 (0%) positive results for chikungunya and 20/20 (100%), 16/20 (80%) and 0/20 (0%) positive results for dengue, respectively. The total, positive and negative agreements between compared methods were 95.5%, 90% and 97.5 for Zika, 100% for all methods for chikungunya and 95.6%, 100% and 94.5%, for dengue, respectively. No cross-reaction was observed.
The authors concluded that the RT-PCR method for simultaneous detection of Zika, chikungunya and dengue viruses is highly sensitive, all assays showed limit of detection below 50 copies/mL. Moreover, cut-off regions were characterized and acceptable precisions were observed for positive (~72 copies/mL and above) and negative (~0.72 copies/mL and below) results. Finally, the agreements with the comparative methods were very good, above 90% of concordance in all instances. The study was presented at the 68th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting held July 31 to August 4, 2016, in Philadelphia, PA, USA.
Related Links:
Laboratório Sabin
American Association of Clinical Chemistry
Detection tests for viral ribonucleic acid (RNA) such as the quantitative reverse transcription polymerase chain reaction (RT-qPCR) can reliably and specifically distinguish the three viruses and the specific diagnosis can be important in anticipating, preventing, and managing complications.
Scientists at the Laboratório Sabin (Brasília, Brazil) and their colleagues collected 90 plasma samples from the routine arbovirus laboratory, 20 positive for Zika (RT-qPCR), six positive for chikungunya (RT-qPCR), 18 positive for dengue nonstructural protein 1 antigen test (NS-1) and 46 negative for all three viruses. Nucleic acids were extracted from 1mL of sample by using an automated DNA extractor. An in-vitro transcribed random RNA sequence, which is not found in the nature, was spiked into plasmas during the nucleic acids extraction to function as a process control. Primers/probes for chikungunya were specifically designed for this study.
Zika, chikungunya and dengue viruses were assessed simultaneously by RT-qPCR, but in independent reaction wells. The control RNA was co-amplified in all instances. The viral loads of specific samples were quantified against a serial dilution of synthetic single-stranded DNA (ssDNA) and the limits of detection of each assay were determined by probit regression analysis. To investigate the precision of the assays, three samples at ~72, ~7.2 and ~0.72 copies/mL of each viruses were evaluated by using the Clinical and Laboratory Standards Institute (CLSI) EP12-A2 method during five days in quadruplicate by two operators.
The investigators reported that the limits of detection were 26 copies/mL for Zika, 23.5 copies/mL, for chikungunya and 25.6 copies/mL for dengue. The ~72, ~7.2 and ~0.72 copies/mL samples yielded 18/20 (90%), 2/20 (10%) and 1/20 (5%) positive results for Zika, 18/20 (90%), 4/20 (20%) and 0/20 (0%) positive results for chikungunya and 20/20 (100%), 16/20 (80%) and 0/20 (0%) positive results for dengue, respectively. The total, positive and negative agreements between compared methods were 95.5%, 90% and 97.5 for Zika, 100% for all methods for chikungunya and 95.6%, 100% and 94.5%, for dengue, respectively. No cross-reaction was observed.
The authors concluded that the RT-PCR method for simultaneous detection of Zika, chikungunya and dengue viruses is highly sensitive, all assays showed limit of detection below 50 copies/mL. Moreover, cut-off regions were characterized and acceptable precisions were observed for positive (~72 copies/mL and above) and negative (~0.72 copies/mL and below) results. Finally, the agreements with the comparative methods were very good, above 90% of concordance in all instances. The study was presented at the 68th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting held July 31 to August 4, 2016, in Philadelphia, PA, USA.
Related Links:
Laboratório Sabin
American Association of Clinical Chemistry
Latest AACC 2016 News
- Derived Exosomal Protein Biomarkers in Alzheimer’s Disease Diagnosis
- New Biochip Array Developed for ApoE4 Classification
- Cell-Free DNA Identifies Liver Transplant Patients with Acute Rejection
- New Method Tested for Early Diagnosis Pediatric Diabetic Nephropathy
- FDA-Cleared Automated Cell Counter for CSF Launched at AACC 2016
- Semen Analysis Portfolio with Two New Products Featured at AACC 2016
- Automation Solutions for Clinical Diagnostic Equipment Showcased at AACC 2016
- New Tubes Designed for Medium Sample Volumes
- Multi Sample Osmometer Improves Testing Efficiency
- Innovative Information System Optimizes Laboratory Processes
- Innovative eLearning Interface Seamlessly Connects Competency Data
- Cloud-Based Connectivity Platform Advances Decentralized Healthcare
- Adhesives Research to Present Hydrophilic Adhesive Technologies
- Point-of-Care Immunoassay Analyzer on Display at AACC Annual Meeting
- Assay for Determination of 17-OH Progesterone to Be Featured at AACC Annual Meeting
- Fully Automated HbA1c Analyzer Available for Inspection at AACC Annual Meeting
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








